Interferon-gamma for treatment of severe atopic eczema in two children.
Two 4- and 5-year-old children suffering from refractory atopic dermatitis were treated with recombinant interferon-gamma (rIFN-gamma). rIFN-gamma was injected at 50 micrograms subcutaneously three times a week in the first child for 3 weeks, followed by three times 25 micrograms in week 4. In the other child two treatment courses of 4 weeks were given after a break of 2 weeks. Therapy was well tolerated. In child one reductions in eczematous body surface and severity of lesions were observed, while no beneficial effect was seen in the other. Clinical chemistry data remained unchanged. Immunological studies performed in parallel showed a decrease in total serum IgE of 50% in child 1, a decrease in spontaneous in vitro IgE production, an increase in in vitro production of interleukin-6, and a normalization of previously decreased in vitro lymphocyte responses to several mitogens. While marked immunological changes were noted during IFN-gamma treatment, clinical benefits were not encouraging. Diminished IFN-gamma production has been claimed to be a major pathogenic factor in atopic eczema. Our results indicate that the pathogenesis is more complex. Clinically, we were unable to confirm previous observations in adults. Further studies are needed before IFN-gamma can be recommended for therapy of pediatric atopic eczema.
Horneff
G
G
Zentrum für Kinderheilkunde, Universität Düsseldorf, Germany.
Dirksen
U
U
Wahn
V
V
D002675:Child, Preschool; D003876:Dermatitis, Atopic / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000096:biosynthesis; D007136:Immunoglobulins / Q000097:blood; D007155:Immunologic Factors / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000627:therapeutic use*; D008213:Lymphocyte Activation; D008297:Male; D011994:Recombinant Proteins
D007136:Immunoglobulins; D007155:Immunologic Factors; D011994:Recombinant Proteins; D007073:Immunoglobulin E; D007371:Interferon-gamma